In China, traditional Chinese
medicine is widely used in the treatment of ischemic stroke, but its
prescription rules needs to be further studied. This paper uses the traditional
Chinese medicine inheritance auxiliary system (a software) to analyze the
composition rules of a large number of prescriptions for the treatment of
ischemic stroke, and discusses the clinical rationality of the new
prescriptions. We found that the prescriptions for the treatment of ischemic
stroke are mainly composed by herbs for promoting blood circulation and
removing blood stasis, dredging collaterals and tonifying deficiency, and some
of the new prescriptions are also in line with this characteristic. This paper
can provide reference for clinical prescription in the treatment of ischemic
stroke and the development of related new drugs.
As a well-known Chinese medicine prescription, Wenxin Keli (WXKL) has
been widely used in the treatment of many arrhythmias including atrial
fibrillation and has achieved significant clinical effects, but the specific
mechanism of its treatment of atrial fibrillation remains unclear. This study
used a network pharmacology approach to reveal the potential molecular
mechanisms of WXKL in the treatment of atrial fibrillation. It involves oral
bioavailability screening of ingredients, drug-likeness evaluation, compound
target fishing, H-C-T network and C-T-P network construction and analysis.
Through the network pharmacology-based research strategy, the complex system of
WXKL was analyzed. It was found that 14 representative compounds of WXKL, 30
protein targets and 12 related signaling pathways help us systematically
understand the underlying mechanism of WXKL's anti-atrial fibrillation effects.
This review provides evidences for the recommendation of acupuncture preconditioning at Neiguan (PC6) point in coronary heart disease patients as a non-pharmacological therapeutic method to activate the miR-214/NCX1 pathway.
The concept of acupuncture preconditioning is described in the ancient book of Fan Wang Fang (Eastern Jin Dynasty of China). It refers to the application of acupuncture before the occurrence of disease or when the disease is relatively mild. According to the record of the ancient book of Huang Di Nei Jing (Qin Han Period of China, 475 B.C.-221 B.C.), acupuncture at Neiguan (PC6) point can prevent and treat angina pectoris in coronary heart disease (CHD). The WHO also recommends acupuncture as one of the alternative and complementary therapies for the prevention and treatment of angina pectoris in CHD.
Early reperfusion of ischemic cardiac tissue is usually the best option to improve clinical outcome of angina pectoris, especially of acute myocardial infarction. However, myocardial reperfusion may cause an abnormal increase of intracellular Ca2+-mediated cardiomyocyte death and consequent loss of cardiac function, which is referred to myocardial ischemia/reperfusion (I/R) injury. Recently, the microRNA-214 (miR-214)/Na+/Ca2+ exchanger (NCX) 1 co-expression is a key factor in cellular protection against myocardial apoptosis for myocardial I/R injury. Once activated, miR-214/NCX1 axis can inhibit several Ca2+ downstream signaling effectors that mediate cell death simultaneously. Studies have shown that acupuncture preconditioning has a protective effect on myocardial I/R injury, but its mechanism deserves further research. It has been proved that acupuncture preconditioning for ischemic myocardium successfully inhibit multiple Ca2+ handling related microRNAs that mediate cell death pathways, and miR-214 is one of its targets. In terms of clinical practice, coronary heart disease (CHD) patients benefit a lot from this intervention. However, there is barely no study correlating acupuncture preconditioning to the miR-214/NCX1 co-expression in patients with CHD. This review aims to discuss whether there is some evidence to justify a recommendation of acupuncture preconditioning in CHD patients as a non-pharmacological therapeutic method to activate the miR-214/NCX1 co-expression network model.
Background:Slow arrhythmia, a common clinical condition, has a higher incidence in the elderly population. Shenxian Shengmai Oral Liquid has been shown to improve the symptoms of patients with slow arrhythmia in many clinical studies and systematic reviews. Sixty participants with slow arrhythmia will be randomized to treatment group (Shenxian Shengmai Oral Liquid) and control group (Shenxian Shengmai Oral Liquid Placebo) in a 2:1 ratio. This clinical trial is a pilot study to compare the effects of Shenxian Shengmai Oral Liquid and the control groups; to analyze the effect of Shenxian Shengmai Oral Liquid for slow arrhythmia.
1.This is the clinical trial plan of oral liquid of Chinese medicine for the treatment of slow arrhythmia.2.This study is a pilot study. Sixty patients with slow arrhythmia were randomly divided into observation group (40 cases) and control group (20 cases) to explore the safety and effectiveness of Shenxian Shengmai Oral Liquid.3.The study will be a randomized, double-blind, placebo-controlled clinical trial.
Intracranial vascular stenosis is closely related to transient ischemic attack (TIA) and cerebral infarction, early prevention and treatment of intracranial vascular stenosis can prevent cerebral infarction and improve the prognosis of stroke. Western medicine employs interventional surgery or vasodilator, antiplatelet drugs, lipid lowering drugs, plaque-stabilizing agents and other drugs for treating intracranial vascular stenosis. No corresponding disease name with “intracranial vascular stenosis” is found in Chinese medicine literature. Based on the characteristics of syndromes, symptoms and diseases, “intracranial vascular stenosis” is summarized as weakened body resistance and prevailed pathogenic factors, phlegm with blood stasis and “obstruction (Bi) syndrome” in the brain. The self-made Chinese herbal “Naomaitong” prescription treating for bilateral middle cerebral artery stenosis in 1 case got satisfactory efficacy by transcranial doppler (TCD) and computed tomography angiography (CTA) examination.
“Intracranial vascular stenosis” has no corresponding name in Chinese medicine literature. The writer summarized it as vessel impediment which location was in the brain with weakened body resistance and pathogenic stagnation, phlegm with blood stasis, based on the characteristics of its symptoms, syndromes and disease. The present study suggested the self-made Chinese herb “Naomaitong” prescription treating for bilateral middle cerebral artery stenosis can get satisfactory effect in clinic.
Atrial fibrillation is of public health importance and profoundly increases morbidity, mortality and health-related expenditures. Morbidities include the increased risks of cardiovascular outcomes such as heart failure and stroke, and the deleterious effects on quality of life, functional status and cognition. Our purpose is to understand the molecular mechanism of atrial fibrillation, a model under pathological conditions should be established. Acetylcholine, a neurotransmitter in the vagus nerve, has been established with numerous atrial fibrillation models. We will discuss the established model of atrial fibrillation which induced by acetylcholine, aiming to seek a model which are more close to the clinical condition. The underlying mechanisms will be discussed in order to observe the mechanism of antiarrhythmic drugs.
Acetylcholine as a neurotransmitter of the vagus nerve which plays an important role in the occurrence and maintenance of atrial fibrillation, is important in basic researches. The acetylcholine is another novel candidate target for atrial-specific drug therapy. The constitutively active form of this current increased in human atrial fibrillation and pharmacological inhibition might be of therapeutic value.
Objective: To observe the effects of the components of Zhilong Huoxue Tongyu Capsule (ZLHXTY) on the expression of NF-κB-P65 and ICAM-1 in blood vessels of rats, and to explore the effect and mechanism of ZLHXTY and its ingredients on vascular remodeling in hypertension. Methods: A rat model of renal hypertension was established by narrowing the left renal artery in the operation group. The corresponding drugs were given once a day respectively. The Normal group, Sham-operation group and Model group were administered with the same volume of normal saline. After 4 weeks of gavage, the thoracic aorta of rat was taken, followed by fixation, embedding, sectioning and HE staining, and NF-κB -p65 was detected by immunohistochemistry. Results: 1. The effect of drugs on the expression of NF-κB in thoracic aorta of hypertensive rats (immunohistochemistry): A small amount of NF-κB protein was expressed in the Normal group and the Sham-operate group. The NF-κB expression in the Model group was significantly increased, and the electron microscope image showed that the brown-yellow granule was distributed in the vascular smooth muscle of the membrane. After treatment, the expression of NF-κB in the Captopril group and the Whole prescription group was significantly reduced compared with the Model group, while the protein expression in other groups was decreased compared with the Model group. The protein expression of captopril group was decreased compared with that of the Whole prescription group. Compared with Promoting blood circulation for removing blood stasis group, the expression of NF-κB in Benefiting qi group was significantly decreased and was similar to that in Warming meridian group. Conclusion: The vascular remodeling mechanism of ZLHXTY on renal hypertension rats may be related to its effects on lowering blood pressure, antioxidant stress and anti-inflammation. After the compatibility of formula produced a significant synergistic effect, and its compatibility after embodies multiple targets for treatment of advantages of traditional Chinese medicine.
By observing the effect of each component of Zhilong Huoxue Tongyu Capsule （ZLHXTY） on the expression of blood vessel NF-κB -P65 and ICAM-1 in rats, to explore the effect of ZLHXTY and its ingredients on vascular remodeling in hypertension and its mechanism. The experimental results indicate that different components of ZLHXTY exert therapeutic effects on vascular remodeling in hypertensive rats from different aspects. Huangqi (Radix Astragali seu Hedysari) plays an important role in lowering blood pressure. The combination of Guizhi (Ramulus Cinnamomi) and Daxueteng (Caulis Sargentodoxae) has a significant effect on the expression of NF- induced B protein. Shuizhi (Hirudo) and compatibility of Dilong (Lumbricus) can lower blood pressure, the NF-κB protein expression. The synergistic effects of the combination of various components are significant, which reflects the therapeutic advantages of multiple targets of traditional Chinese medicine.
As a chronic disease that seriously endangers public health, the number of coronary heart disease (CHD) patients in China has increased in recent years. There is great potentiality to integrate traditional Chinese and Western medicine therapies to prevent and treat CHD in clinical practice. However, most of the current integrated therapies still lack sufficient high-quality evidence, and the key links in how to apply are unclear. It is urgent to optimize them through evidence-based research to further improve the effectiveness. Therefore, we propose strategies to conduct evidence-based optimization of integrated traditional Chinese and Western medicine therapies in prevention and treatment of progressive cardiovascular diseases. These are integrated clinical trial design, attention to the key links of taking effect, combination of clinical and basic research. Based on the strategies, we started the national key research and development project "Evidence-based optimization research of TCM therapies in prevention and treatment of CHD (angina pectoris - myocardial infarction - heart failure)", which is expected to be a new paradigm in the field.
Copyright © TMR Publishing Group.